Document Detail

Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
MedLine Citation:
PMID:  8504497     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Staphylokinase (STA), a protein with known profibrinolytic properties, is produced by transduced Staphylococcus aureus strains. In experimental animal models, recombinant staphylokinase (STAR) is less immunogenic and more active toward platelet-rich arterial blood clots than streptokinase. METHODS AND RESULTS: In the present study, 10 mg STAR given intravenously over 30 minutes was found to induce angiographically documented coronary artery recanalization within 40 minutes in four of five patients with acute myocardial infarction. Plasma fibrinogen and alpha 2-antiplasmin levels were unaffected, and allergic reactions were not observed. Postinfusion disappearance of STAR antigen followed a biphasic mode with a t1/2 alpha of 6.3 +/- 0.6 minutes (mean +/- SD) and a t1/2 beta of 37 +/- 15 minutes, corresponding to a plasma clearance of 270 +/- 100 mL/min. Neutralizing antibodies against STAR could not be demonstrated at baseline and up to 6 days after infusion, but STAR neutralizing activity, which did not cross-react with streptokinase, was consistently demonstrable in plasma at 14-35 days. CONCLUSIONS: STAR can induce clot-selective coronary thrombolysis in patients with evolving myocardial infarction without concomitant induction of a systemic lytic state. STAR, a small protein that can be easily produced by recombinant DNA technology, may therefore offer promise for thrombolytic therapy in patients with thromboembolic disease.
D Collen; F Van de Werf
Related Documents :
19744277 - Magnesium sensitive, adenosine resistant, repetitive monomorphic ventricular tachycardia.
21290557 - Ventricular septal defect closure in a small children with the amplatzer duct occluder ii.
8883267 - Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degrad...
21529737 - Implications of progressive aberrancy versus true fusion for diagnosis of wide complex ...
21855837 - Effect of prolonged bivalirudin infusion on st-segment resolution following primary per...
20214147 - Pattern and possible contributing factors to dialysis-associated arrhythmia in young pa...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Circulation     Volume:  87     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-07-02     Completed Date:  1993-07-02     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1850-3     Citation Subset:  AIM; IM    
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Angiography
Coronary Vessels / physiopathology
Metalloendopeptidases / pharmacokinetics,  therapeutic use*
Middle Aged
Myocardial Infarction / drug therapy*,  radiography
Pilot Projects
Recombinant Proteins / pharmacokinetics,  therapeutic use
Thrombolytic Therapy*
Time Factors
Vascular Patency / physiology
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.24.-/Metalloendopeptidases; EC protein, Staphylococcus aureus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myocardial infarct size can be estimated from serial plasma myoglobin measurements within 4 hours of...
Next Document:  X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dyst...